The Scientific Advisory Board (SAB) for Susan G. Komen for the Cure® provides strategic guidance and direction for the Komen organization, in particular the research and scientific programs, and has played a key role in guiding and prioritizing Komen’s global research investment. The SAB also serves as the executive committee of the Komen Scholars.The SAB is led by the chief scientific advisor(s) and is comprised of leaders in breast cancer research, clinical practice and advocacy who have made significant contributions to advancing the field and are committed to furthering Komen’s mission.
Eric P. Winer, M.D., is chief scientific advisor and co-chair of the Scientific Advisory Board for Susan G. Komen for the Cure. In addition to his responsibilities at Susan G. Komen for the Cure, Dr. Winer serves as chief, Division of Women’s Cancers and the Thompson Senior Investigator in Breast Cancer Research at Dana-Farber Cancer Institute, where he leads a multidisciplinary group of clinicians and investigators focused on caring for individuals with breast cancer and identifying new and better approaches to treatment. He is also a professor of Medicine at Harvard Medical School. Dr. Winer received his undergraduate and medical degrees from Yale University. After completing internal medicine and medical oncology training at Yale and Duke, he was on the faculty at Duke Medical Center for eight years before moving to Dana-Farber Cancer Institute in 1997. Dr. Winer is co-chair of the Alliance Breast Committee. Read more | Play video
George W. Sledge, M.D., is chief scientific advisor and co-chair of the Scientific Advisory Board for Susan G. Komen for the Cure. In addition to his responsibilities at Susan G. Komen for the Cure, Dr. Sledge is also the Chief of Oncology at Stanford University. A pioneer in the development of novel therapies for breast cancer, Dr. Sledge was awarded the Brinker Award for Scientific Distinction in 2006. His research specifically focuses on molecular and tumor biology, growth factors and anti-angiogenic therapy. He has chaired several nationwide clinical trials involving new therapies for breast cancer.
Carlos L. Arteaga, M.D., is professor of Medicine and Cancer Biology at Vanderbilt University School of Medicine, director of Breast Cancer Research Program and associate director for Clinical Research at Vanderbilt-Ingram Cancer Center. His research focuses on explaining the role of several key growth factor receptors and signaling pathways, including pathways that are responsible for breast cancer cell growth, division, and metastasis, in the pathogenesis of breast cancer, with the goal of developing drugs that target these proteins to treat breast cancer. Dr. Arteaga was awarded the Brinker Award for Scientific Distinction in 2011.
Myles Brown, M.D., is professor of Medicine at Harvard Medical School and director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute. His research focuses on understanding the role of steroid hormones receptors and their co-regulators in breast and prostate cancers.
Powel Brown, M.D., Ph.D., is professor and chair of the Department of Clinical Cancer Prevention, John Charles Cain distinguished chair, and professor in the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center. His laboratory and clinical efforts are focused on developing novel strategies for the treatment and prevention of estrogen receptor-negative (ER-negative) breast cancer. Play video
Karen Gelmon, M.D., is a professor of Medicine and medical oncologist at the University of British Columbia and clinical leader of the Experimental Therapeutics department at the British Columbia Cancer Agency. She is also co-chair of the Breast Cancer Committee for the NCIC-Clinical Trials Group. Dr. Gelmon combines clinical and translational research in her work. Her research focuses on developing improved treatment options for persons with breast cancer and spans Phase I, II, and III clinical trials as well as research to understand the character of cancer and its effect on patients.
Cheryl Jernigan, CPA, FACHE, is a 17-year breast cancer "thriver" and breast health advocate. She is a founding and current board member, and chair of the Strategic Mission Committee of the Greater Kansas City Affiliate of Susan G. Komen for the Cure; a member of the steering committee for the Komen Advocates in Science; and treasurer for the Susan G. Komen Advocacy Alliance's Board of Directors. She is also Immediate Past Chair of The Advancement Board, co-chair of the Cancer Funding Partners, and Chair of the Breast Cancer Prevention Center Advocate Advisory Board for The University of Kansas Medical Center and The University of Kansas Hospital; A member of the Clinical Trials Transformation Initiative's Patient Leadership Council; a past member of the National Cancer Institute's Director's Consumer Liaison Group (DCLG); and has served as an advocate reviewer for Komen's Research Program, the U.S. Congressionally-Directed Breast Cancer Research Program, and the Lance Armstrong Foundation.
Amelie G. Ramirez, Dr.PH, an internationally recognized cancer and chronic disease health disparities researcher and spokesperson, is a professor of epidemiology and biostatistics at The University of Texas Health Science Center at San Antonio, where she also is founding director of the Institute for Health Promotion Research, which researches health disparities among minorities. Dr. Ramirez’s research focuses on public health and health disparities affecting Hispanics/Latinos and other populations. Play video